

Supplement Tables

Supplement Table 1 Extraction Recovery

No	LQC			MQC			HQC		
	Peak area (pre- extraction)	Peak area (post- extraction)	Recovery%*	Peak area (pre- extraction)	Peak area (post- extraction)	Recovery%*	Peak area (pre- extraction)	Peak area (post- extraction)	recovery%*
1	5372.2	11534.5	45.7	52570.6	118517.3	44.6	137336.7	242456.2	55.1
2	4687.9	11800.7	39.9	57768.9	118044.7	49.0	130380.2	249190.7	52.3
3	5352.2	11734.7	45.5	57335.4	118391.1	48.7	143869.4	261768.1	57.8
4	5891.2	11748.4	50.1	55295.5	117248.8	46.9	128743.1	243091.6	51.7
5	6323.2	11660.2	53.8	56261.7	119300.0	47.7	121993.0	250117.4	49.0
6	6014.9	12027.3	51.2	58538.1	115570.5	49.7	136534.1	247821.1	54.8
Average	5606.9	11751.0	47.7	56295.0	117845.4	47.8	133142.8	249074.2	53.5
SD	587.3	163.8	5.00	2152.1	1298.9	1.84	7687.1	6977.1	3.09
%CV	10.5	1.4	10.5	3.8	1.1	3.8	5.8	2.8	5.8
Average Recovery%		47.7			47.8			53.5	
Total Recovery%					49.7				
Total Recovery SD					3.32				
Total %CV					6.7				

Note: "*" Individual recovery formula: the peak area of the analyte in the extracted QC samples/ the average peak area of the analyte in blank matrix post extraction spiked the same concentration $\times 100$

Supplement Table 2 Summary of incurred sample reanalysis assessment results for 94 randomly selected human plasma samples

Sample No.	Initial concentration ng/mL	Reassay concentration ng/mL	Difference %
1	30.4	27.9	-8.6
2	31.6	29.8	-5.9
3	11.5	10.2	-12.0
4	15.8	15.1	-4.5
5	5.57	4.89	-13.0
6	2.43	2.18	-10.8
7	3.31	2.99	-10.2
8	4.49	4.39	-2.3
9	4.50	4.60	2.2
10	2.32	2.22	-4.4
11	33.0	30.5	-7.9
12	12.5	10.7	-15.5
13	27.7	27.5	-0.7
14	32.6	30.5	-6.7
15	3.40	3.42	0.6
16	2.23	1.99	-11.4
17	2.92	2.82	-3.5
18	4.25	4.05	-4.8
19	16.0	15.2	-5.1
20	15.4	13.6	-12.4
21	23.4	21.7	-7.5
22	23.3	21.8	-6.7

Sample No.	Initial concentration ng/mL	Reassay concentration ng/mL	Difference %
23	3.41	3.08	-10.2
24	2.21	1.87	-16.7
25	2.33	2.28	-2.2
26	2.88	3.81	27.8
27	10.0	9.86	-1.4
28	4.97	4.53	-9.3
29	2.95	2.42	-19.7
30	9.66	8.76	-9.8
31	1.57	1.41	-10.7
32	2.21	2.15	-2.8
33	2.54	2.07	-20.4
34	16.6	19.8	17.6
35	26.6	25.4	-4.6
36	12.8	11.4	-11.6
37	15.1	14.1	-6.8
38	2.78	2.37	-15.9
39	2.13	1.97	-7.8
40	2.16	1.87	-14.4
41	3.47	3.05	-12.9
42	30.5	28.2	-7.8
43	19.0	16.4	-14.7
44	5.70	4.69	-19.4
45	10.4	9.41	-10.0
46	2.08	1.97	-5.4

Sample No.	Initial concentration ng/mL	Reassay concentration ng/mL	Difference %
47	3.39	2.94	-14.2
48	2.55	2.24	-12.9
49	1.93	1.89	-2.1
50	30.6	29.2	-4.7
51	4.99	4.69	-6.2
52	13.7	12.7	-7.6
53	3.99	3.47	-13.9
54	2.16	1.80	-18.2
55	1.63	1.39	-15.9
56	2.29	2.13	-7.2
57	4.91	4.55	-7.6
58	29.2	27.8	-4.9
59	3.35	3.12	-7.1
60	12.3	11.2	-9.4
61	11.4	10.8	-5.4
62	1.95	1.50	-26.1
63	2.20	2.00	-9.5
64	2.41	2.40	-0.4
65	4.39	4.11	-6.6
66	12.2	12.7	4.0
67	18.2	18.0	-1.1
68	16.0	15.1	-5.8
69	5.44	5.10	-6.5
70	2.08	1.76	-16.7

Sample No.	Initial concentration ng/mL	Reassay concentration ng/mL	Difference %
71	2.39	2.22	-7.4
72	3.06	2.90	-5.4
73	3.35	3.28	-2.1
74	16.1	16.5	2.5
75	7.25	7.33	1.1
76	3.79	3.77	-0.5
77	5.97	6.10	2.2
78	1.77	1.68	-5.2
79	1.70	1.65	-3.0
80	2.08	2.16	3.8
81	2.94	3.31	11.8
82	34.1	32.8	-3.9
83	26.2	26.6	1.5
84	30.3	29.5	-2.7
85	31.4	30.0	-4.6
86	3.76	4.44	16.6
87	6.84	6.64	-3.0
88	5.63	5.46	-3.1
89	4.51	4.80	6.2
90	19.0	18.6	-2.1
91	3.01	2.37	-23.8
92	5.09	4.54	-11.4
93	1.85	1.71	-7.9
94	2.48	2.43	-2.0

Sample No.	Initial concentration ng/mL	Reassay concentration ng/mL	Difference %
Total Sample Number for ISR			94
Sample Number Passing ISR Acceptance Criteria			90
Percentage of the ISR Passing Rate (%)			95.7%